These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

288 related items for PubMed ID: 15074858

  • 1. Evaluation of suspected pituitary pars intermedia dysfunction in horses with laminitis.
    Donaldson MT, Jorgensen AJ, Beech J.
    J Am Vet Med Assoc; 2004 Apr 01; 224(7):1123-7. PubMed ID: 15074858
    [Abstract] [Full Text] [Related]

  • 2. Lamellar pathology in horses with pituitary pars intermedia dysfunction.
    Karikoski NP, Patterson-Kane JC, Singer ER, McFarlane D, McGowan CM.
    Equine Vet J; 2016 Jul 01; 48(4):472-8. PubMed ID: 25869529
    [Abstract] [Full Text] [Related]

  • 3. Factors associated with survival, laminitis and insulin dysregulation in horses diagnosed with equine pituitary pars intermedia dysfunction.
    Horn R, Bamford NJ, Afonso T, Sutherland M, Buckerfield J, Tan RHH, Secombe CJ, Stewart AJ, Bertin FR.
    Equine Vet J; 2019 Jul 01; 51(4):440-445. PubMed ID: 30417404
    [Abstract] [Full Text] [Related]

  • 4. Plasma fructosamine concentrations in horses with pituitary pars intermedia dysfunction with and without laminitis.
    Knowles EJ, Menzies-Gow NJ, Mair TS.
    Equine Vet J; 2014 Mar 01; 46(2):249-51. PubMed ID: 23663105
    [Abstract] [Full Text] [Related]

  • 5. BEVA primary care clinical guidelines: Diagnosis and management of equine pituitary pars intermedia dysfunction.
    Menzies-Gow NJ, Banse HE, Duff A, Hart N, Ireland JL, Knowles EJ, McFarlane D, Rendle D.
    Equine Vet J; 2024 Mar 01; 56(2):220-242. PubMed ID: 37795557
    [Abstract] [Full Text] [Related]

  • 6. Association between hyperinsulinaemia and laminitis severity at the time of pituitary pars intermedia dysfunction diagnosis.
    Tadros EM, Fowlie JG, Refsal KR, Marteniuk J, Schott HC.
    Equine Vet J; 2019 Jan 01; 51(1):52-56. PubMed ID: 29761574
    [Abstract] [Full Text] [Related]

  • 7. The oral glucose test predicts laminitis risk in ponies fed a diet high in nonstructural carbohydrates.
    Meier AD, de Laat MA, Reiche DB, Pollitt CC, Walsh DM, McGree JM, Sillence MN.
    Domest Anim Endocrinol; 2018 Apr 01; 63():1-9. PubMed ID: 29172109
    [Abstract] [Full Text] [Related]

  • 8. The prevalence of endocrinopathic laminitis among horses presented for laminitis at a first-opinion/referral equine hospital.
    Karikoski NP, Horn I, McGowan TW, McGowan CM.
    Domest Anim Endocrinol; 2011 Oct 01; 41(3):111-7. PubMed ID: 21696910
    [Abstract] [Full Text] [Related]

  • 9. Case series of equine pituitary pars intermedia dysfunction in a tropical climate.
    Spelta CW, Axon JE.
    Aust Vet J; 2012 Nov 01; 90(11):451-6. PubMed ID: 23106327
    [Abstract] [Full Text] [Related]

  • 10. Phenotypic, hormonal, and clinical characteristics of equine endocrinopathic laminitis.
    de Laat MA, Sillence MN, Reiche DB.
    J Vet Intern Med; 2019 May 01; 33(3):1456-1463. PubMed ID: 30697823
    [Abstract] [Full Text] [Related]

  • 11. Evaluation of the effects of age and pituitary pars intermedia dysfunction on corneal sensitivity in horses.
    Miller C, Utter ML, Beech J.
    Am J Vet Res; 2013 Jul 01; 74(7):1030-5. PubMed ID: 23802675
    [Abstract] [Full Text] [Related]

  • 12. Adrenocorticotropin concentration following administration of thyrotropin-releasing hormone in healthy horses and those with pituitary pars intermedia dysfunction and pituitary gland hyperplasia.
    Beech J, Boston R, Lindborg S, Russell GE.
    J Am Vet Med Assoc; 2007 Aug 01; 231(3):417-26. PubMed ID: 17669045
    [Abstract] [Full Text] [Related]

  • 13. Investigation of rhythms of secretion and repeatability of plasma adrenocorticotropic hormone concentrations in healthy horses and horses with pituitary pars intermedia dysfunction.
    Rendle DI, Litchfield E, Heller J, Hughes KJ.
    Equine Vet J; 2014 Jan 01; 46(1):113-7. PubMed ID: 23742059
    [Abstract] [Full Text] [Related]

  • 14. Circannual variation in plasma adrenocorticotropic hormone concentrations in the UK in normal horses and ponies, and those with pituitary pars intermedia dysfunction.
    Copas VE, Durham AE.
    Equine Vet J; 2012 Jul 01; 44(4):440-3. PubMed ID: 21848531
    [Abstract] [Full Text] [Related]

  • 15. Investigation of single and paired measurements of adrenocorticotropic hormone for the diagnosis of pituitary pars intermedia dysfunction in horses.
    Rendle DI, Duz M, Beech J, Parkin T, Durham AE.
    J Vet Intern Med; 2015 Jan 01; 29(1):355-61. PubMed ID: 25312676
    [Abstract] [Full Text] [Related]

  • 16. Effects of pituitary pars intermedia dysfunction and Prascend (pergolide tablets) treatment on endocrine and immune function in horses.
    Miller AB, Loynachan AT, Bush HM, Hart KA, Barker VD, Campana-Emard AG, Grubbs ST, Adams AA.
    Domest Anim Endocrinol; 2021 Jan 01; 74():106531. PubMed ID: 32942194
    [Abstract] [Full Text] [Related]

  • 17. The use of adrenocorticotrophic hormone as a potential biomarker of pituitary pars intermedia dysfunction in horses.
    Lee ZY, Zylstra R, Haritou SJ.
    Vet J; 2010 Jul 01; 185(1):58-61. PubMed ID: 20537574
    [Abstract] [Full Text] [Related]

  • 18. Age over 25 years, but not plasma adrenocorticotropic hormone con-cen-tration above the seasonally adjusted reference range is predictive for radio-graphically assessed changes of chronic laminitis in elderly horses.
    Christen G, Precht C, van der Kolk J, Fouché N, Gerber V.
    Schweiz Arch Tierheilkd; 2020 Dec 01; 162(12):781-785. PubMed ID: 33263545
    [Abstract] [Full Text] [Related]

  • 19. Fecal strongyle egg counts in horses with suspected pre-clinical pituitary pars intermedia dysfunction before and after treatment with pergolide.
    Christen G, Gerber V, van der Kolk JH, Frey CF, Fouché N.
    Vet J; 2018 May 01; 235():60-62. PubMed ID: 29704940
    [Abstract] [Full Text] [Related]

  • 20. Pharmacokinetics and pharmacodynamics of pergolide mesylate after oral administration in horses with pituitary pars intermedia dysfunction.
    Rendle DI, Doran G, Ireland J, Edwards S.
    Domest Anim Endocrinol; 2019 Jul 01; 68():135-141. PubMed ID: 31082785
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.